Search
Clinical Watch List Resources
Thank you for submitting your request. Your resource is now available for download, along with some additional materials that may be of interest:
New drugs, renewed hope: Strengthening antimicrobial stewardship
The rise of multidrug-resistant (MDR) organisms is limiting treatment options for critically ill patients, while the challenge of antimicrobial resistance (AMR) puts patient outcomes at risk. Thermo Fisher Scientific is combating AMR by collaborating early with pharmaceutical companies to introduce novel antimicrobials to the market and antimicrobial susceptibility landscape, ensuring their effective integration into clinical practice.
Learn more about this partnership in our white paper featuring a spotlight on the new antifungal Rezafungin by Melinta Therapeutics.
Outsmarting superbugs: Optimizing mycobacterial phenotypic drug susceptibility testing
Learn how modern microbiology can tackle TB and nontuberculous mycobacterial (NTM) challenges with our new white paper where we explore the importance of comprehensive drug susceptibility testing for effective management and surveillance.
Infographic: Superbug surcharge - The economics of MDROs and HAIs
In our new infographic, Superbug surcharge: The economics of MDROs and HAIs, we take a closer look at the financial and patient impact of superbugs, and how advancements in screening, detection, and treatment can help healthcare facilities control the consequences of MDROs and HAIs, leading to better patient outcomes.
White paper: Defending against the rising threat of drug-resistant fungal sepsis
Understanding the complexity of fungal sepsis caused by Candida species may seem daunting, but one thing is certain: Appropriate laboratory diagnostics like AST and emerging research can help turn the tide in the fight against fungal sepsis. Read our latest white paper, Defending against the rising threat of drug-resistant fungal sepsis as we explore current challenges, as well as tactical considerations for laboratories and new innovations in the battle against antifungal resistance.
Case study: Using definitive MIC, therapeutic drug monitoring and PK/PD data to help optimize patient outcomes and combat AMR
At Bologna University Hospital in Italy, Prof. Federico Pea and his team have developed a comprehensive and interdisciplinary program to tailor antibiotic therapy based on accurate minimum inhibitory concentration (MIC) values, real-time therapeutic drug monitoring (TDM) data, and pharmacokinetic/pharmacodynamic (PK/PD) parameters. Learn more about their approach, which aims to support optimized patient outcomes while helping to prevent the emergence of antibiotic resistance and preserve the future of antibiotics.
Laboratory legend: How your AST results support accurate antibiotic therapy in the battle against bacterial sepsis
Sepsis, the body’s extreme response to infection, remains a significant health concern globally. In the context of MDROs, bacterial agents like E. coli and Klebsiella spp. force difficult decision-making in healthcare settings. For these challenging infections, timely and accurate antimicrobial susceptibility testing (AST) plays a crucial role in determining the right antimicrobials to kill the bacteria or stop it from spreading, thereby helping the body’s natural immune system to fight the infection that causes severe sepsis.
In this white paper, we take a look at the critical role of AST in guiding antibiotic therapy, different methodologies, and best practices to enhance laboratory accuracy and communication.
The high cost and human toll of multidrug-resistant organisms (MDROs)
Every minute counts when MDROs can cause healthcare-associated infections (HAIs) – infections patients acquire during healthcare treatment. These infections can quickly spiral out of control and become costly and deadly emergencies. Labs and clinicians make consequential decisions each and every day as pathogens, such as MRSA, Acinetobacter baumannii and Clostridioides difficile, become more prevalent and present greater risks to patients and hospital operations.
But while clinicians and labs may feel the odds are stacked against them in preventing MDROs and the dangerous and costly HAIs they can cause, there is hope. Let's explore the new tools, techniques, and clinical perspectives that can help even the score.
Featured solutions
 | Detect, presumptively identify and screen samples for pathogenic and non-pathogenic organisms with speed and accuracy using our wide range of chromogenic media. |
 | Optimize antimicrobial selection to support targeted treatment and better patient outcomes with the power of definitive minimum inhibitory concentration (MIC) results. |
 | Perform simple, flexible manual AST with the ease of disc diffusion, as well as the latest antimicrobials in a full range of concentrations, for maximum reproducibility. |
 | Ensure reproducible test results with quality control material that you can trust. |
For more information on our solutions for supporting the fight against AMR, request a quote or demonstration or visit thermofisher.com/onehealth.
Style Sheet for Global Design System
Style Sheet for Komodo Tabs